1-甲基-3-苯基-1H-[1,2,4]噻唑 | 39696-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-3-苯基-1H-[1,2,4]噻唑
• 英文名称: 1-methyl-3-phenyl-1H-1,2,4-triazole
• 英文别名: 1-Methyl-3-phenyl-1,2,4-triazol；1-methyl-3-phenyl-1H-[1,2,4]triazole；1-Methyl-3-phenyl-1H-[1,2,4]triazol；1-methyl-3-phenyl-1,2,4-triazole
• CAS: 39696-58-7
• 化学式: C₉H₉N₃
• mdl: MFCD11044603
• 分子量: 159.191
• InChiKey: WNJZGUZYODIDKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲基-3-苯基-1H-[1,2,4]噻唑 、 正丁基锂 、 3-(t-butyldimethylsilanyloxy)-5-ethyl-2-fluorobenzaldehyde 在 氯化铵 、 乙酸乙酯 、 水 、 Brine 、 Sodium sulfate-III 、 crude product 、 EtOAc hexanes 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以to afford 440 mg of Example 368.3的产率得到(3-(tert-butyldimethylsilyloxy)-5-ethyl-2-fluorophenyl)(2-methyl-5-phenyl-2H-1,2,4-triazol-3-yl)methanol
  参考文献：
  名称：

  Heterocyclic compounds as inhibitors of factor VIIa

  摘要：

  本发明涉及一般抑制丝氨酸蛋白酶的化合物。特别是，它是针对新型杂环化合物或其立体异构体或药学上可接受的盐、溶剂或前药形式的选择性抑制凝血级联反应中的丝氨酸蛋白酶酶类的有用抑制剂；例如凝血酶、VIIa因子、Xa因子、XIa因子、IXa因子和/或血浆激肽。特别是，它涉及到是VIIa因子抑制剂的化合物。本发明还涉及包含这些化合物的制药组合物和使用它们的方法。

  公开号：

  US07576098B2
• 作为产物：
  描述：

  1-Methyl-3-phenyl-1,2,4-triazol-5-carbonsaeure-methylester 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以78%的产率得到1-甲基-3-苯基-1H-[1,2,4]噻唑
  参考文献：
  名称：

  Fliege, Werner; Grashey, Rudolf; Huisgen, Rolf, Chemische Berichte, 1984, vol. 117, # 3, p. 1194 - 1214

  摘要：

  DOI：

文献信息

• Copper-Catalyzed Oxidative C(sp³)–H Functionalization for Facile Synthesis of 1,2,4-Triazoles and 1,3,5-Triazines from Amidines
  作者：Huawen Huang、Wei Guo、Wanqing Wu、Chao-Jun Li、Huanfeng Jiang

  DOI：10.1021/acs.orglett.5b00995

  日期：2015.6.19

  facile and versatile catalytic system involving copper catalyst, K3PO4 as the base, and O2 as the oxidant has been developed to enable efficient synthesis of 2,4,6-trisubstituted and 2,6-disubstituted 1,3,5-triazines and 1,3-disubstituted 1,2,4-triazoles from amidines with trialkylamines, DMSO, and DMF as the reaction partners, respectively. This protocol features inexpensive metal catalyst, green oxidant

  已经开发了一种简便而通用的催化体系，该体系涉及铜催化剂，K 3 PO 4为碱和O 2为氧化剂，以实现2,4,6-三取代和2,6-二取代的1,3,5的高效合成。 tri与三烷基胺，DMSO和DMF分别作为反应伙伴时，由am生成的-三嗪和1,3-二取代的1,2,4-三唑。该协议具有廉价的金属催化剂，绿色氧化剂，良好的官能团耐受性和高区域选择性的特点，可有效进入那些用传统方法难以制备的产品。提出了用于这些转化的单电子转移（SET）机制。
• USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS
  申请人：LANGER Nicolle

  公开号：US20120007063A1

  公开（公告）日：2012-01-12

  The present invention relates to the use of dibenzofurans and dibenzothiophenes which have at least one nitrogen-bonded five-membered heterocyclic ring as a substituent as host, blocker and/or charge transport material in organic electronics. The present invention further relates to dibenzofurans and dibenzothiophenes which comprise at least one nitrogen-bonded five-membered heterocyclic ring and at least one carbazolyl radical as substituents, to a process for preparation thereof, and to the use of these compounds in organic electronics.

  本发明涉及在有机电子器件中将至少含有一个氮键合的五元杂环环作为取代基的二苯并呋喃和二苯并噻吩用作主体、阻挡剂和/或电荷传输材料。本发明还涉及至少含有一个氮键合的五元杂环环和至少一个咔唑基团作为取代基的二苯并呋喃和二苯并噻吩，以及其制备方法和在有机电子器件中的应用。
• 3-Substituted Propanamine Compounds
  申请人：Park Chun-Eung

  公开号：US20100311789A1

  公开（公告）日：2010-12-09

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

  本发明涉及由以下结构式(I)表示的混合或对映富集的3-取代丙胺化合物或其药学上可接受的盐。本发明还涉及含有该化合物的制药组合物。所述化合物对于治疗中枢神经系统疾病，如抑郁症、焦虑症和疼痛障碍，具有有用性。
• Dihydro-1,2,4-triazin-6(1H)-ones. III. Oxidation Products of 1-Methyl-3-phenyl- 4,5-dihydro-1,2,4-triazin-6(1H)-one
  作者：David J. Collins、Timothy C. Hughes、Wynona M. Johnson

  DOI：10.1071/ch99047

  日期：——

  1-Methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one (1) undergoes aerial oxidation to give a mixture of 1- methyl-3-phenyl-1,2,4-triazin-6(1H)-one (2) and 1-methyl-3-phenyl-1,4-dihydro-1,2,4-triazine-5,6-dione (3). The dehydro derivative (2) was cleanly prepared by the oxidation of (1) with 2,3-dichloro-5,6-dicyano-1,4- benzoquinone (ddq). The dehydro derivative (2) underwent a surprising rearrangement to the triazole (12) upon oxidation with OxoneR. Several attempts at unambiguous synthesis of the α-dicarbonyl derivative (3) were unsuccessful; it was obtained, together with the 1,4-dimethyl derivative (13) by methylation of 3-phenyl-1,4- dihydro-1,2,4-triazine-5,6-dione (4) with sodium hydride and methyl iodide.

  1-Methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one (1) 经过气相氧化，得到 1-甲基-3-苯基-4,5-二氢-1,2,4-三嗪-6(1H)-酮 甲基-3-苯基-1,2,4-三嗪-6(1H)-酮 (2) 和 1-methyl-3-phenyl-1,4-dihydro-1,2,4-triazine-5,6-dione (3).脱氢 衍生物(2)是由(1)与 2,3-二氯-5,6-二氰基-1,4-苯醌 (ddq)。脱氢衍生物 (2) 在与 OxoneR。为明确合成 α-二羰基衍生物 (3) 的几次明确合成尝试均未成功；它与 1,4-二甲基衍生物 通过甲基化 3-苯基-1,4-二氢-1,2,4-二甲基-1,4-二羰基衍生物 (13) 二氢-1,2,4-三嗪-5,6-二酮 (4) 与氢化钠和甲基碘进行甲基化反应，得到了 1,4-二甲基衍生物 (13)。
• 3-SUBSTITUTED PROPANAMINE COMPOUNDS
  申请人：Park Chun-Eung

  公开号：US20120046312A1

  公开（公告）日：2012-02-23

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

  本文披露了由以下结构式（I）表示的外消旋或对映富集的3-取代丙胺化合物或其药学上可接受的盐。本文还披露了含有该化合物的药物组合物。该化合物对于治疗中枢神经系统疾病，如抑郁症、焦虑症和疼痛障碍非常有用。